|
[posting]60971449[/posting]Am Donnerstag ist die FDA-Entscheidung hoffen wir mal das beste .... Kommentar unten gehört mit zum Buy rating von Wainwright: “We have valued Eton based on a discounted cash flow (DCF) assessment, driven by our projection of future sales and royalty-based revenue from three candidates in the company’s pipeline, namely EM-100, ET-202 and CT-100. Our valuation approach utilizes a 12% discount rate and 2% terminal growth rate, along with a 28% effective tax rate applied to future cash flows. We assign a 90% probability of regulatory approval to EM-100, an 85% probability of approval to ET-202, which have already been filed with the 80% probability of approval to ET-103.”,” the firm’s analyst commented. |
|
| aus der Diskussion: | ETON (Mkap $133 M) 3x FDA-Entscheide + Multiple NDA-Anträge in kürze |
| Autor (Datum des Eintrages): | Biohero (07.07.19 21:57:33) |
| Beitrag: | 14 von 309 (ID:60972637) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |